FDA’s proposed “hub-and-spoke” drug registration rule: what it could change

FDA has proposed rule changes that would modernize how some distributed drug manufacturing networks register with the agency and update information over time. FDA also proposes clarifications for certain foreign manufacturing sites that indirectly supply the U.S. drug market.

The proposal—issued July 10, 2026 and published in the Federal Register on July 13—targets “hub-and-spoke” manufacturing networks, where a centralized quality oversight “hub” supports multiple equivalent manufacturing “spokes” at other locations. FDA says existing rules can require separate registrations for each location, even when the network operates under one management and quality oversight structure.

What FDA is proposing for “hub-and-spoke” networks

FDA’s framework centers on how an “establishment” is defined in current regulations (tied to “one general physical location”). FDA says that definition doesn’t fit distributed manufacturing models, where the quality oversight hub and manufacturing units may not share one general physical location.

Under the proposal, qualifying distributed manufacturing establishments (DMEs) could register as a single establishment using a hub-and-spoke model—grounded in the idea of one quality unit at the hub implementing a unified pharmaceutical quality system (UPQS) to oversee and control manufacturing across equivalent units at the spokes.

How the proposal would work when networks add, remove, or relocate units

FDA would use an expedited-update structure for changes in the network. In the proposal, the timing depends on whether a change is treated as an addition/removal-type update or a mobile unit relocation.

• Adding a new unit (DMU): update the DME’s registration no later than 5 calendar days after a domestic DMU begins manufacturing for commercial distribution, or before a drug manufactured at a foreign DMU is imported or offered for import into the United States.
• Removing a unit or other specified changes: update registration information no later than 30 calendar days after events FDA lists in the proposal, including removing a distributed manufacturing unit, changing the distributed manufacturing hub’s physical address, closing or selling a distributed manufacturing establishment, and certain changes to the official contact or the U.S. agent.
• Relocating a mobile unit: provide advance notice at least 30 calendar days prior to relocation within (or to) the United States, and at least 120 calendar days prior to relocation within (or to) a foreign country. After arrival, the registrant would then update the registration once manufacturing has commenced—no later than 5 calendar days after a domestic DMU begins manufacturing, or before import/offer-for-import for drugs manufactured at a foreign DMU.

What changes for certain foreign drug manufacturing sites

On the foreign side, FDA proposes clarifications intended to align registration and drug listing expectations with the statutory requirements for certain foreign establishments engaged in manufacturing that results in drugs entering the U.S. drug supply.

The proposal would clarify that when those foreign establishments manufacture drugs (including active pharmaceutical ingredients) that are imported or offered for import into the United States, the registration and drug listing expectations apply regardless of whether the drug undergoes further manufacturing at another foreign establishment prior to import.

Why this matters for public health and accountability

FDA says registration and drug listing information support core agency responsibilities such as inspection planning, postmarket monitoring, and responses to safety concerns and supply disruptions. Better, more network-aware registration data is also intended to improve the agency’s visibility into how and where drugs are being made as manufacturing footprints change.

For patients and families, the practical “why” is speed and clarity during problems—when recalls, shortages, or quality issues require rapid traceability across a complex supply chain.

What U.S. readers should watch next

This is not a final rule. The public comment period runs until September 11, 2026.

Expect the most important debate in comments to focus on how FDA defines which distributed manufacturing networks qualify for the “single establishment” pathway and how companies must handle expedited updates—especially for mobile unit relocations and foreign manufacturing scenarios that feed indirectly into the U.S. drug supply.

If finalized, the biggest compliance shift could be toward a more network-based registration approach for qualifying hub-and-spoke DMEs, alongside clearer expectations for certain foreign establishments that supply drugs for import into the United States.

Sources

• FDA press announcement (July 10, 2026): Proposes Rule to Modernize Drug Manufacturing Registration
• Federal Register proposed rule (July 13, 2026): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments

Look for updates to this story

Related News

• West Nile Virus Detected in Barnstable Mosquitoes
• Worcester schedules mosquito spraying after West Nile detection
• Ellijay water-main rupture triggers boil-water advisory for Progress Road area
• Berwyn opens new multi-use Community Field near Baseball Alley